A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of CL-197 Capsules Administered in Single Dose in Healthy Participants
Latest Information Update: 30 Apr 2024
At a glance
- Drugs CL 197 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors HeNan Sincere Biotech Co. Ltd
Most Recent Events
- 23 Apr 2024 Status changed from recruiting to completed.
- 19 Jul 2023 New trial record